BN
BNR.US Burning Rock Biotech Ltd
- Market cap
- USD 140M
- P/E
- -
- P/B
- 1.85x
- ROE
- -14.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BNR.US undervalued?
Graham numberThe Graham number of Burning Rock Biotech Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Burning Rock Biotech Ltd fundamental analysis
No fundamental analysis for Burning Rock Biotech Ltd yet.
Burning Rock Biotech Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, pros…
Full company profileBurning Rock Biotech Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Burning Rock Biotech Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 111M | 209M | 382M | 430M | 508M | 563M | 537M | 516M | 540M | 486M |
| Gross Profit | 71.7M | 135M | 273M | 314M | 364M | 380M | 363M | 362M | 403M | 352M |
| Operating Income | -121M | -161M | -169M | -412M | -797M | -980M | -669M | -358M | -54.8M | -73.7M |
| EBITDA | -99.6M | -136M | -129M | -373M | -746M | -845M | -518M | -270M | -32.0M | -65.9M |
| Net Income | -131M | -177M | -168M | -407M | -797M | -971M | -654M | -347M | -55.3M | -71.8M |
| EPS | -73 | -79 | -72 | -59 | -76 | -93 | -64 | -34 | -51 | -66 |
| Balance Sheet | ||||||||||
| Total Assets | 400M | 373M | 848M | 2.66B | 2.28B | 1.59B | 1.04B | 885M | 821M | 751M |
| Total Liabilities | 232M | 976M | 1.74B | 242M | 433M | 429M | 272M | 304M | 285M | 254M |
| Shareholders' Equity | 168M | -603M | -891M | 2.42B | 1.85B | 1.16B | 768M | 581M | 536M | 497M |
| Cash & Short-term Investments | 190M | 130M | 408M | 2.26B | 1.50B | 905M | 615M | 520M | 481M | 419M |
| Total Debt | 169M | 272M | 67.5M | 46.9M | 86.7M | 50.8M | 12.3M | 52.3M | 43.1M | 45.1M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -134M | -149M | -228M | -73.5M | -478M | -457M | -256M | -92.3M | -28.4M | -103M |
| Capital Expenditure | 23.0M | 24.7M | 45.7M | 79.5M | 213M | 62.0M | 9.38M | 5.98M | 5.25M | 10.5M |
| Free Cash Flow | -157M | -173M | -274M | -153M | -691M | -519M | -265M | -98.2M | -33.7M | -103M |
| Ratios | ||||||||||
| ROE | -77.9% | - | - | -16.8% | -43.2% | -83.8% | -85.1% | -59.7% | -10.3% | -14.4% |
| ROA | -32.8% | -47.6% | -19.9% | -15.3% | -35.0% | -61.2% | -62.9% | -39.2% | -6.7% | -9.6% |
| Net Profit Margin | -118.1% | -85.0% | -44.1% | -94.7% | -156.9% | -172.4% | -121.6% | -67.2% | -10.3% | -14.8% |
| Debt to Equity | 1.00x | - | - | 0.02x | 0.05x | 0.04x | 0.02x | 0.09x | 0.08x | 0.09x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Burning Rock Biotech Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | CNY 360M | 53 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on May 15, 2024.
Who owns Burning Rock Biotech Ltd
- Insiders 4.03%
- Institutions 47.47%
- Public & others 48.50%
- Shares outstanding 8.81M
- Free float 3.42M
Top funds holding BNR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 53.9K | 0.51% | +22.33% | Jun 2026 |
| Fidelity Nasdaq Composite Index | 4.22K | 0.04% | 0.00% | Aug 2026 |
| DFA Emerging Markets Core Equity 2 I | 570.00 | 0.01% | -58.09% | Aug 2026 |
| DFA World ex US Core Equity Instl | 301.00 | 0.00% | 0.00% | Sep 2026 |
| DFA Emerging Markets Small Cap I | 189.00 | 0.00% | -79.39% | Aug 2026 |
Top institutions holding BNR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Kynam Capital Management, LP | 1.24M | 11.74% | +0.90% | Jun 2026 |
| CRCM LP | 424K | 4.02% | +50.30% | Jun 2026 |
| Renaissance Technologies Corp | 52.8K | 0.50% | +49.23% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 43.6K | 0.41% | +185.45% | Jun 2026 |
| Amova Asset Management Americas, Inc | 29.7K | 0.28% | -1.37% | Jun 2026 |
| Sumitomo Mitsui Trust Group Inc | 29.7K | 0.28% | -1.37% | Jun 2026 |
| Bank of America Corp | 29.2K | 0.28% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 27.3K | 0.26% | +54.44% | Jun 2026 |
| HSG Holding Ltd | 21.2K | 0.20% | 0.00% | Jun 2026 |
| UBS Group AG | 17.9K | 0.17% | +4,291.18% | Jun 2026 |
| Almanack Investment Partners, LLC. | 16.2K | 0.15% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 13.6K | 0.13% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.80K | 0.03% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.24K | 0.01% | +4,335.71% | Jun 2026 |
| JPMorgan Chase & Co | 166.00 | 0.00% | -11.23% | Jun 2026 |
| Royal Bank of Canada | 73.00 | 0.00% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.00 | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Burning Rock Biotech Ltd company profile
- Company name
- Burning Rock Biotech Ltd
- Ticker
- BNR.US
- Exchange
- USA Stocks
- Listed since
- Jun 12, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 667
- Fiscal year end
- December
- Address
- No. 5, Xingdao Ring Road North, Guangzhou, China, 510005
- Phone
- 86 20 3403 7871
- Website
- brbiotech.com
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Burning Rock Biotech Ltd management
5- Mr. Yusheng HanFounder, Chairman & CEO · born 1979
- Ms. Xiaozhi HuVice President of Finance · born 1984
- Dr. Zhihong ZhangCTO & Director · born 1976
- Mr. Hao LiuSenior Advisor · born 1974
- Dr. Xinru MaoSenior VP of Pharma Biomarker & CDx. Services and International Diagnostics Division